Depomed Inc  

(Public, NASDAQ:DEPO)   Watch this stock  
Find more results for David Dawes
10.89
-0.15 (-1.36%)
Real-time:   2:50PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.85 - 11.26
52 week 6.12 - 15.39
Open 11.11
Vol / Avg. 579,024.00/1.10M
Mkt cap 629.38M
P/E 9.56
Div/yield     -
EPS 1.14
Shares 57.79M
Beta 1.38
Inst. own 78%
Aug 6, 2014
Q2 2014 Depomed Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2014
Q2 2014 Depomed Earnings Release - 4:00PM EDT - Add to calendar
Jun 24, 2014
Depomed Inc at JMP Securities Healthcare Conference
Jun 18, 2014
Depomed Inc at Wells Fargo Healthcare Conference
Jun 3, 2014
Depomed at Jefferies Global Healthcare Conference - Webcast
May 20, 2014
Depomed Annual Shareholder Meeting
May 19, 2014
Depomed at UBS Global Healthcare Conference - Webcast
May 15, 2014
Depomed at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Q1 2014 Depomed Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Depomed Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 23.44% 32.27%
Operating margin 46.70% 6.94%
EBITD margin - 11.53%
Return on average assets 14.72% 13.32%
Return on average equity 48.33% 39.13%
Employees 291 -
CDP Score - -

Address

SUITE 300, 7999 GATEWAY BLVD.
NEWARK, CA 94560
United States - Map
+1-510-7448000 (Phone)
+1-510-7448001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Depomed, Inc. (Depomed) is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system. In January 2011, the United States Food and Drug Administration (FDA) approved Gralise (gabapentin) once-daily tablets for the management of postherpetic neuralgia. The Company is developing and commercializing a number of pharmaceutical products for neurology, pain and other central nervous system conditions and diseases. The Company�s products include Gralise, Glumetza, Serada and DM-1992. Gralise (gabapentin) is its once-daily formulation of gabapentin for the management of postherpetic neuralgia (PHN). Glumetza is the Company's once-daily treatment for adults with type 2 diabetes that is commercialized in the United States by Santarus, Inc. (Santarus). In June 2012, the Company acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc.

Officers and directors

Peter D. Staple Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
James A. Schoeneck President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
August J. Moretti Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Matthew M. Gosling Senior Vice President, General Counsel
Age: 43
Bio & Compensation  - Reuters
Srinivas G. Rao M.D., Ph.D. Chief Medical Officer and Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Thadd M. Vargas Senior Vice President - Business Development
Age: 48
Bio & Compensation  - Reuters
Steve L. Greco Vice President - Sales
Age: 64
Bio & Compensation  - Reuters
Kevin D. Weber Vice President - Marketing
Age: 56
Bio & Compensation  - Reuters
Jeff P. Coon Vice President - Human Resources
Age: 51
Bio & Compensation  - Reuters
Gerd G. Kochendoerfer Vice President - Technical Development and Quality
Age: 46
Bio & Compensation  - Reuters